Chargement en cours...
Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa
We evaluated Eastern Cooperative Group phase II and III trials E2696 and E1694 to assess the incidence and prognostic significance of autoimmunity induced by adjuvant high-dose interferon-α2b (HDI). In E2696, patients with resectable high-risk melanoma were randomized to receive vaccination with GM2...
Enregistré dans:
| Publié dans: | Melanoma Res |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4308690/ https://ncbi.nlm.nih.gov/pubmed/24509407 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000050 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|